Your browser doesn't support javascript.
loading
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot, J M; Bigenwald, C; Champiat, S; Collins, M; Carbonnel, F; Postel-Vinay, S; Berdelou, A; Varga, A; Bahleda, R; Hollebecque, A; Massard, C; Fuerea, A; Ribrag, V; Gazzah, A; Armand, J P; Amellal, N; Angevin, E; Noel, N; Boutros, C; Mateus, C; Robert, C; Soria, J C; Marabelle, A; Lambotte, O.
Affiliation
  • Michot JM; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpitaux de Paris, Hôp
  • Bigenwald C; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Champiat S; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Collins M; Gastroenterology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; Université Paris Sud 11, F-94275 Le Kremlin-Bicêtre, France.
  • Carbonnel F; Gastroenterology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; Université Paris Sud 11, F-94275 Le Kremlin-Bicêtre, France.
  • Postel-Vinay S; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Berdelou A; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Varga A; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Bahleda R; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Hollebecque A; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Massard C; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Fuerea A; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Ribrag V; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Gazzah A; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Armand JP; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Amellal N; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Angevin E; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Noel N; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; Université Paris Sud 11, F-94275 Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, Division of Immunovirology, IDMIT, F-92265 Fontenay-aux-Roses,
  • Boutros C; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpitaux de Paris, Hôp
  • Mateus C; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpitaux de Paris, Hôp
  • Robert C; Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpitaux de Paris, Hôp
  • Soria JC; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Marabelle A; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
  • Lambotte O; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; Université Paris Sud 11, F-94275 Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, Division of Immunovirology, IDMIT, F-92265 Fontenay-aux-Roses,
Eur J Cancer ; 54: 139-148, 2016 Feb.
Article in En | MEDLINE | ID: mdl-26765102
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / Immunotherapy / Antibodies / Neoplasms / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Eur J Cancer Year: 2016 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / Immunotherapy / Antibodies / Neoplasms / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Eur J Cancer Year: 2016 Document type: Article Country of publication: Reino Unido